NMD Pharma - Inkef capital
NMD Pharma - Inkef capital
Biotech completes financing round to advance neuromuscular treatments - EPM Magazine
Management — NMD Pharma
NMD Pharma is Strengthening Muscles in Neuromuscular Disorders
News — NMD Pharma
NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
NMD Pharma
Thomas Holm Pedersen - Chief Executive Officer, Associate professor of Physiology and Biophysics in Aarhus, Arhus, Denmark | eMedEvents
Biopeople Newsletter January 2020 - Biopeople
NMD Pharma - PIR International
Thomas Holm Pedersen – CEO – NMD Pharma | LinkedIn
Oct 23 | Neuromuscular Drug Development Summit (NMD) | Boston, MA Patch
Foundations invest DKK 280 million in biomedical company
NMD Pharma raises €38M (~USD 47 Million) SERIES A Financing to Advance Treatments of Neuromuscular Disorders
NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
NMD Pharma A/S | LinkedIn
Management — NMD Pharma
ALS Therapy Developer NMD Pharma Obtains $47 Million in New Financing
NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
Management — NMD Pharma
NMD Pharma A/S | LinkedIn
NMD Pharma treats first patient with the firm's most promising drug candidate
Prominent Canadian researcher in Denmark: Why I left a top job in California
Rare Neuromuscular Disease Company NMD Pharma Raises USD 3 Million in Seed Financing Round - Lundbeckfonden
